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The objective of this study was to determine the incidence of pulmonary involvement in patients with systemic lupus 
erythematosus (SLE) and to clarify the clinical and laboratory characteristics in SLE patients with various 
pulmonary involvements. 
A retrospective study (12 = 137) revealed that the types of pulmonary involvement found in SLE patients were: 
pleuritis (9%) interstitial pneumonia (8%) pulmonary infarction (7%), pulmonary infection (4%) pulmonary 
hypertension (2%) restrictive dysfunction (28%) and decreased diffusion capacity (43%). The incidences of 
pericarditis (P<O.Ol), arthralgia (P<O.O5) and hypoalbuminemia (PcO.05) were significantly greater in patients with 
pleuritis than in those without, while in patients with interstitial pneumonia, the incidence of anti-SS-A antibody 
(P<O.O5) and sicca syndrome (P<O.O5) were significantly greater than in those without. A longitudinal follow-up 
study of patient groups with various pulmonary involvements revealed: 1. significant changes of erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP): lactate dehydrogenase (LDH) and thrombomodulin (TM) in 
patients with pleuritis, and 2. significant changes of WBC and LDH in patients with interstitial pneumonia. 
The increased ESR; CRP and TM levels during disease episodes suggest that the involvement of inflammatory 
processes is related to vasculitic events in the pathogenesis of lupus pleuritis. A higher incidence of anti-SS-A 
antibody in lupus patients with interstitial pneumonia suggests a potential role for this autoantibody in the 
pathogenesis of this complication. 
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Introduction 
Systemic lupus erythematosus (SLE) is a chronic systemic 
disease which can involve many organ systems such as the 
central nervous system; lung, kidney and skin. Patients with 
SLE have been shown to have a number of pulmonary 
complications, including pleuritis, interstitial pneumonia, 
pulmonary hypertension, pulmonary infarction, pulmonary 
haemorrhages and infectious pneumonia (14). Moreover; 
abnormalities in pulmonary function tests such as restric- 
tive changes and a decreased diffusion capacity for carbon 
monoxide (DLCO) have been reported in patients with SLE 
regardless of the apparent pulmonary involvement (5). In 
the present study, we analysed the types and frequencies of 
pulmonary involvement and characterized the clinical and 
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laboratory findings in lupus patients with pulmonary 
diseases. 
Patients and Methods 
PATIENTS 
One hundred and thirty-seven consecutive patients with 
SLE who were being actively followed-up by the Collagen 
Disease Clinic at the International Medical Center of Japan 
were identified from the files, Patients with SLE who 
fulfilled four or more of the revised American College of 
Rheumatology (ACR) criteria for SLE (6) and whose 
clinical records were available for review were selected in 
June 1995. The following data were collected: sex; age; 
year of disease onset; complete clinical history, including 
arthralgia, fever, cutaneous lesions, photosensitivity, 
alopecia, cardiovascular disease, Raynaud’s phenomenon, 
respiratory disease, genitourinary disease; central nervous 
system and psychiatric disorders, abdominal complaints; 
oral ulcers, serositis; sicca symptoms; and a complete list of 
present medications. 
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The mean & SD and range of the age at observation, the 
age at onset and the duration of disease were 42 f 12 years 
and 20-79 years; 27 & 11 years and 5-58 years and 15 * 7 
years and 4-39 years, respectively. The female:male ratio 
was 127:lO. 
Using the patients’ notes, which charted the entire 
clinical history of the disease, the presence or absence of the 
following clinical and laboratory findings were investigated 
in the 137 patients: malar or discoid rash, photosensitivity, 
oral ulcers, alopecia, arthritis, arthralgia, pericarditis, 
pleuritis (defined by the presence of characteristic pain, 
characteristic friction rub, and radiographical findings), 
interstitial pneumonia (defined by radiographical and/or 
computerized tomographic findings), pulmonary infarction 
(defined by pulmonary angiography and/or lung scanning), 
pneumonia (defined by bacterial and fungal infection of 
which the causative agents were determined), pulmonary 
hypertension (defined by a mean pulmonary artery pressure 
exceeding 25 mmHg which was measured by right cardiac 
catheterization or Doppler echocardiography), restrictive 
pulmonary disease [a forced vital capacity (FVC) of ~80% 
predicted], decreased DLCO (~70% predicted), convulsions, 
psychosis, thrombosis, spontaneous abortions, sicca syn- 
drome, persistent proteinuria 20.5 g day ~ ’ or greater than 
3+ if quantification was not performed), cellular casts, 
decreased creatinine clearance (Ccr, _< 60 ml min - I), 
haemolytic anaemia, leukopenia (~4000 mm - 3), lympho- 
penia (~1500mm-~), thrombocytopenia (<lo5 mmp3), 
presence of fluorescent anti-nuclear antibodies (FANA), 
LE cells and positive LE test, presence of anti-double 
stranded (ds) DNA antibodies, anti-Ul-RNP, anti-Sm, 
anti-SS-A and anti-SS-B antibodies [assayed using enzyme- 
linked immunosorbent assay (ELISA) kits (Medical 
Biological Laboratory, Nagoya, Japan)], anti-cardiolipin 
antibodies, circulating immune complexes, low C3 
(< 60 mg dl - ‘) and low C4 (< 10 mg dl - ‘) levels, biological 
false positives for syphilis (BFPs), lupus anticoagulants, 
hypoalbuminemia (~3.5 g dl - ‘) and elevated erythrocyte 
sedimentation rate (ESR, > 30 min h- ‘). 
The presence or absence of the following clinical and 
laboratory findings was studied longitudinally, in 23 SLE 
patients with pulmonary involvement (12 with pleuritis and 
11 with interstitial pneumonia) 6 months before an episode 
(-6M), during an episode (OM) and at 6 months after an 
episode (+6M), from May 1979 to July 1994 by a retrospec- 
tive chart review; malar rash, discoid rash, photosensitivity, 
alopoecia, oral ulcers, arthritis, convulsions, psychosis, 
pleuritis, pericarditis, dyspnoea, sputum, chest pain, cough 
or fine crepitation, pulmonary hypertension (mean pulmon- 
ary artery pressure >25 mmHg), proteinuria (>3+ or 
> 0.5 g day - ‘), cellular cast, haemolytic anaemia, leuko- 
penia (~4000 mme3), lymphopenia (cl500 mme3), throm- 
bocytopenia (< 10’ mm- 3), BFPs, FANA, medication (oral 
corticosteroid, corticosteroid pulse therapy or immuno- 
suppressants). Values for the following were obtained in 
laboratory studies: IgG anti-ds and single-stranded DNA 
antibodies, IgG, IgM, IgA, circulating immune com- 
plexes, C3, C4, ESR, C-reactive protein (CRP), white 
blood cell count (WBC), lactate dehydrogenase (LDH), 
thrombomodulin (TM) and prednisolone levels. 
Disease activity in the lupus patients was scored by 
counting the number of the following variables present: 
1. fever (‘37°C) 2. arthralgia, 3. malar rash, 4. oral ulcers 
or alopecia, 5. hypocomplementemia (C3: > 60 mg dl - ’ or 
C4: > 10 mg dl~ I), 6. hypoalbuminemia (~3.5 g dl- I), 7. 
elevated ESR (a30 mmh- I), 8. LE cells or positive LE 
test. The disease activity score was evaluated at - 6M, OM, 
and at +6M. Patients were judged to be suffering from 
active disease when the score was 64. 
METHODS 
Assay for thvombomodulin 
Thrombomodulin levels in serum samples which had been 
stored at - 20°C were measured using a one-step sandwich 
ELISA developed by Fuji Chemical Industries (Takaoka, 
Japan (7). 
STATISTICAL ANALYSIS 
Data are reported as means *SD. Data analysis was per- 
formed with StatFlex software (ViewFlex Co. Ltd., Tokyo, 
Japan) using the Wilcoxon test, chi-squared text, Fisher’s 
exact test, Spearman’s rank-sum test or the Mann-Whitney 
U-test as appropriate. Differences of PcO.05 were 
considered statistically significant. 
Results 
Table 1 shows the types and frequencies of pulmonary 
involvement found in the 137 SLE patients. Isolated DLCO 
reduction without restrictive or obstructive change was 
found in 14 of 74 (19%) patients. No statistically significant 
differences in mean age or sex ratio were found between 
patients with pulmonary involvement or abnormal pulmon- 
ary function tests and those who did not have these 
pulmonary problems. 
The incidence of abnormal clinical and laboratory find- 
ings throughout the clinical history of the disease in lupus 
patients with pulmonary involvement was compared to that 
in patients with no pulmonary involvement. As shown in 
Fig. l(a), the incidences of pericarditis (P<O.Ol), arthralgia 
(PcO.05) and hypoalbuminemia (PcO.05) were significantly 
greater in patients with pleuritis than in those without, 
while the incidence of anti-SS-A antibody was significantly 
lower (PcO.05) in patients with pleuritis than in those 
without. As shown in Fig. l(b), the incidences of anti-SS-A 
antibodies (PcO.05) and sicca syndrome (PcO.05) were 
significantly greater in patients with interstitial pneumonia 
than in those without, while the incidence of malar rash 
(PcO.05) was significantly lower. Patients with pulmonary 
infarction had a significantly greater incidence of lupus 
anticoagulants (P<O.Ol), decreased DLCO (P<O.O5), spon- 
taneous abortion (PcO.05) and decreased Ccr (PcO.05) 
than those without pulmonary infarction [Fig. l(c)]. In 
patients with pulmonary infections (n = 5), the frequency of 
decreased DLCO (4, 80%) was significantly greater than 
those without pulmonary infections (27, 20%, P<O.Ol; 
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TABLE 1. Types and frequencies of pulmonary involvement or abnormal pulmonary function tests in 
patients with SLE 
Types of pulmonary 
involvement and abnormal 





Mean & SD 
Sex ratio 
EM 
Pleuritis 12 (9) 45* 15 IO:2 
Interstitial pneumonia 11 (8) 41+ 10 1l:O 
Pulmonary infarction 9 (7) 41* 8 9:o 
Pulmonary infection 5 (4) 41 It 15 5:o 
Pulmonary hypertension 2 (2) 32 zt 4 2:o 
Restrictive changes 23 (29)* 43!= 16 23:l 
Decreased DLCO 33 (45Yt 44f 12 30:2 
Whole SLE 137 42% 12 127:lO 
D~CO=diffusion capacity for carbon monoxide; n=number of patients; “Forced vital capacity was 
tested in 78 patients and “yDLC0 in 74 patients. 
Fisher’s exact test). Patients with restrictive dysfunction 
(%FVC ~80% predicted) and a significantly greater inci- 
dence of elevated erythrocyte sedimentation rate (P<O.Ol) 
and LE test [P<O.O5, Fig. l(d)] and those with decreased 
diffusion capacity (DLCO: ~70% predicted) had a signifi- 
cantly greater incidence of Raynaud’s phenomenon 
(P<O,OOl), proteinuria (P<O.Ol), leukopenia (P<O.Ol), 
lymphopenia (PcO.05) and decreased Ccr [P<O.O5, 
Fig. l(e)]. 
The median and interquartile range of the prednisolone 
dosage given at OM (40 and 1348 mg day- ‘) were signifi- 
cantly higher than those recorded at - 6M (10 and 
O-10 mg day-‘, PcO.05) and those at +6M (10 and 
lo-20 mg day ~ ‘, PcO.05). In addition, methylpred- 
nisolone pulse therapy was administered to one (3%) of 12 
patients, while an immunosuppressive agent (cyclo- 
phosphamide) was given to three (25%). The follow-up 
study of lupus patients with pleuritis revealed that: 1. the 
incidence of dyspnoea at OM (5, 42%) was significantly 
higher than at +6M (0, O%, PcO.05; 2. the frequency of 
chest pain at OM (7, 58%) was significantly higher than at 
- 6M (1, 8%, P<O,O5) and that at +6M (1, 9%, PcO.05); 3. 
the incidence of coughs at OM (5, 42%) was significantly 
higher than at - 6M (0, O%, PcO.05) and at +6M (0, O%, 
PO.05); 4. the incidence of pericarditis at OM (5, 42%) was 
significantly higher than at - 6M (0, O%, P<O,O5) and at 
+6M (0, O%, PcO.05); 5. the number of patients with active 
disease at OM (7, 58%) was significantly higher than at 
- 6M (1, 8%, NO.05) and at +6M (0: O%, PcO.05); 6. the 
median and interquartile ranges of IgA at - 6M (294, 
250463 mg d ~ ‘) were significantly higher than at OM (261, 
1799387 mg dl- ‘) and at +6M (223, 167436 mg dll I; 
P<O.O5); 7. the median and interquartile ranges of the ESR 
(Westergren) at OM (80: 44-l 12 mm h - ‘) were significantly 
higher than at +6M (35; 9944mm hh’, PcO.01); 8. the 
median and interquartile ranges of CRP levels at OM 
(4.9, 2.1-6.3 mg dll ‘) were significantly higher than at 
+6M (0.5, 0.2-0.7 mg dll’, PcO.05); 9. the median and 
interquartile ranges of LDH at OM (347, 215417 mg dl~ ‘) 
were significantly higher than at - 6M (201, 187- 
288 mg dl ~ I; PcO.05) and at + 6M 123 1, 194-309 mg dl - ‘, 
PcO.01, Fig. 2(a)]; and 10. the median and interquartile 
ranges of the TM levels at OM (8.6, 3.2-9.9 FU ml - ‘) were 
significantly higher than at - 6M (3.5, 2.5-5.4 FU ml - I, 
PcO.05) and at +6M [4.6, 2.6-6.3 FUml-‘, P<O.Ol, 
Fig. 3(a)]. 
The median and interquartile range of the dosage of 
prednisolone given at OM (40, 5-60 mg day- ‘) was signifi- 
cantly higher than those at - 6M (12.5, 5-23.8 mg day- ‘, 
P<O.O5) and at +6M (12.5, 5-15mgdayy’, P<O.O5). 
In addition, methylprednisolone pulse therapy was under- 
taken in four (36%) of the 11 patients and immuno- 
suppressive agents were given to three (27%) patients 
(cyclophosphamide to two and azathioprine to the other). 
The follow-up study of lupus patients with interstitial 
pneumonia revealed that: 1. the incidence of dyspnoea at 
OM (5, 45%) was significantly higher than at +6M (0: O%, 
PcO.05); 2. the incidence of coughing at OM (7, 64%) was 
significantly higher than at +6M (1, 9%, PcO.05); 3. the 
incidence of sputum at OM (7, 64%) was significantly 
higher than at -6M (1; 9%; PcO.05) and at +6M 
(1, 9%, PcO.05); 4. the incidence of fine crepitation at OM 
(5, 45%) was significantly higher than at +6M (0, O%, 
PcO.05); 5. the median and interquartile range of the 
WBC at OM (6100, 4000-6850mm-3) were significantly 
higher than at +6M (4400, 3578-5250 mme3, PcO.05 by 
Wilcoxon test; 6. the median and interquartile range of the 
LDH levels at OM (271, 197-580 IU l- ‘) were significantly 
higher than those at - 6M [204, 161-252 IU l- ‘, P<O.Ol; 
Fig. 2(b)]. 
The median and interquartile ranges of the ESR (80, 
44.3-l 12.3 mm h - I), CRP (4.85, 2.10-6.25 mg dl - ‘) and 
WBC (8200, 5950-11300 mmd3) in patients with pleuritis 
were significantly higher than in patients with interstitial 
pneumonia (45, 37.0-60.5 mm h- I, PcO.05; 0.60, 0,20- 
3.75 mg dll ‘, P<O.O5; 6100, 4000-6850 mm- 3, P<O.O5). 
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FIG. 1. Conditions with significantly different frequencies between patients with and without pleuritis (a), interstitial 
pneumonia (b), puImonary infarction (c), restrictive dysfunction (d) and decreased diffusion capacity (e). Significantly 
more frequent compared to patients without the respective pulmonary involvement (***:P<O.OOl, **:P<O.Ol, *:P<O.O5) 
and significantly less frequent compared to patients without the respective pulmonary involvement (#:P<O.O5). 
Discussion pulmonary infarction, during the history of the disease in 
patients with SLE. 
We have demonstrated a significant incidence of pulmonary 
complications, such as pleuritis, interstitial pneumonia and 
In SLE patients with pleuritis as a complication, the 
incidence of pericarditis, arthralgia and hypoalbuminemia 
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FIG. 2. Longitudinal change of serum lactate dehydrogenase (LDH) levels in patient with pleuritis (a) and those with 
interstitial pneumonia (b). n.s. =not significant. 
were significantly greater than in those without pleuritis. 
Estes et al. (2) reported that 16 out of 60 (27%) lupus 
patients with pleuritis had nephrotic syndrome. In our 
study, four out of 12 (33%) such patients had nephrotic 
syndrome. Our longitudinal study of patients with 
pleuritis revealed significant elevation of serum TM levels 
during episodes, suggesting that some mechanism related to 
damage of the endothelial cells (i.e. increased capillary 
permeability) might be involved in the pathogenesis of 
pleuritis (8). Conditions such as arthralgia and hypo- 
albuminemia were thought to be associated with SLE 
activity and in fact seven (58%) of our patients with 
pleuritis had active disease at the time of their pleuritic 
episode. 
The levels of ESR and CRP and WBC counts during 
episodes of SLE in patients with pleuritis were greater than 
those in lupus patients with interstitial pneumonia. Usually, 
SLE patients with active disease tend not to have signifi- 
cantly elevated CRP levels (9,lO) and often have leuko- 
penia. Thus, the elevation of CRP and WBC counts during 
SLE episodes in these pleuritic patients was somewhat 
peculiar, suggesting the involvement of specific inflamma- 
tory processes in the pathogenesis of lupus pleuritis, prob- 
ably in response to specific cytokines released by activated 
immunoinflammatory cells. Moreover, a large mass of 
inflammatory cells, which is characteristic of pleuritis, may 
lead to elevation of CRP and WBC. Bouros et al. (11) 
reported that massive bilateral pleural effusion could be the 
only first manifestation of SLE. Although our pleuritic 
patients had all developed full-blown disease at the onset of 
pleuritis, SLE should always be borne in mind when 
examining patients whose sole symptom is massive pleural 
effusion. 
In SLE patients with the complication of interstitial 
pneumonia, the incidences of anti-SS-A antibodies and 
sicca syndrome were significantly greater than in those 
without pulmonary involvement. Boulware et al. (12) 
reported an incidence of 25% for lupus pneumonitis among 
63 SLE patients and revealed that as many as 81% of 
patients with lupus pneumonitis have anti-SS-A (Ro) anti- 
bodies, compared with 38% for the entire group with SLE 
(P<O.OOl). Simmons-O’Brien et al. (13) followed 100 
patients (including 50 with SLE) who were positive for 
anti-SS-A antibody and found five with SLE and interstitial 
pneumonia. Hedgpeth et al. (14) reviewed all inpatients 
seen at their rheumatology service from 1984 to 1986 and 
found that 10 of the 12 patients with SLE and interstitial 
pneumonia had antibodies to SS-A. 
The association of lupus pneumonitis and anti-SS-A 
antibodies may result from a speculative immunopatho- 
genie role of the antibody to SS-A antigen. It has been 
suggested that in SLE, immune complexes with anti-SS-A 
antibodies are selectively deposited within the lung, thus 
initiating an inflammatory response. Alternatively, any 
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FIG. 3. Longitudinal change of serum thrombomodulin (TM) levels in patients with pleuritis (a) and those with interstitial 
pneumonia (b). n.s. =not significant. 
inflammatory stimulus inciting alveolitis may induce 
reactive alveolar lining cells to increase the expression of the 
SS-A antigen on their cell surfaces, as is seen in keratino- 
cytes after UV light irradiation (15). This SS-A surface 
antigen could bind to anti-SS-A antibodies in the circula- 
tion, thereby enhancing the inflammatory reaction. More- 
over, it is possible that cross-reactivity between the SS-A 
antigen and other similar alveolar cell surface epitopes 
occurs in the lungs of patients with SLE. 
The significant elevation of LDH during episodes of SLE 
in patients with either pleuritis or interstitial pneumonia 
indicates that this parameter is useful in the management of 
these pulmonary conditions. Although the mechanism 
underlying the elevation of serum LDH during episodes of 
these pulmonary complications is not clear, it is possible 
that LDH might be released from damaged inflammatory 
or parenchymal cells surrounding the lesion (16). There 
is also in vitro evidence of LDH leakage from type II 
pneumocytes, pulmonary endothelial cells and alveolar 
macrophages, following a number of insults such as 
hypoxia. The significant elevation of TM during disease 
episodes in SLE patients with pleuritis indicates that 
measurement of this variable would be useful in the man- 
agement of these patients. TM levels did not rise in patients 
with interstitial pneumonia, suggesting that damage to 
vascular endothelial cells may not be involved in this 
condition. The increase in TM levels during pleuritic 
episodes might be caused by its release from damaged 
vascular endothelial cells. The TM molecule consists of 
fragments with various molecular weights which are prob- 
ably degraded proteolytically from cellular TM, or may be 
derived from the injured and/or inflamed endothelial cells 
(17). 
Abnormalities in pulmonary function tests, such as 
decreased DLCO and restrictive changes, were also com- 
mon regardless of apparent presence of pulmonary involve- 
ment. It has been reported that weakness of the diaphragm 
and other respiratory muscles is an important feature in at 
least 25% of SLE patients (l&19). As to the frequencies of 
the pulmonary function abnormality in SLE, the restrictive 
change was found in 24 of 78 (28%) patients and the 
reduction in diffusing capacity was found in 32 of 74 (43%) 
patients in our study. These frequencies were almost com- 
parable with those reported in previous reports (i.e. restric- 
tive change: 1049%; decreased DLCO: 31-94%), although 
backgrounds of patients in these reports were widely diverse 
in terms of the complication of the pulmonary disease 
(20-23). As to the clinical and laboratory correlates of the 
pulmonary function abnormality, we found that the restric- 
tive change is associated with a positive LE test and 
elevated ESR and the decreased DLCO is relevant to 
Raynaud’s phenomenon, decreased Ccr, proteinuria, leuko- 
penia and lymphopenia. The correlation of the restrictive 
change with positive LE test and elevated ESR may be 
interpreted as a reflection of the increased disease activity 
of SLE. The correlation of the decreased DLCO with 
Raynaud’s phenomenon and renal involvement (decreased 
Ccr and proteinuria) may be explained by the presence of 
the vasculitic change common to the lung, digits and the 
kidney. In contrast to our study, Silberstein et al. (22) 
reported that no correlation was found in either the classi- 
fication or severity of the pulmonary function abnormality 
when compared with other measures of lupus activity, such 
as serology, immune complexes in skin biopsy, and renal 
biopsy. Andonopoulos et al. (23) also reported that no 
correlation was observed between major organ involvement 
or a specific serological pattern and respiratory function 
abnormalities. 
In conclusion, the increase in the levels of ESR, CRP, 
TM and WBC counts during episodes suggests the involve- 
ment of inflammatory processes related to vascular events 
in the pathogenesis of lupus pleuritis. The higher fre- 
quencies of anti-SS-A antibodies in lupus patients who have 
interstitial pneumonia suggests the possible significance of 
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